How do you apply vaginal estrogen cream?
Vaginal estrogen cream is inserted into the lower part of the vagina, with the applicator that comes with the product or a finger, on a schedule that starts out daily for a couple of weeks and then drops to a few times a week. A small amount of the same cream can also be smoothed over the vulva and the vaginal opening, where many of the symptoms of genitourinary syndrome of menopause (GSM) are often felt. The single most useful rule is to follow the instructions for your specific product, because the approved creams differ in strength and in how they are measured.
The usual schedule
Cream regimens typically follow a loading-then-maintenance pattern: roughly daily for about two weeks, then a step down to a few times a week. In the recurrent-UTI guideline, one well-studied regimen used estriol vaginal cream 0.5 mg nightly for two weeks and then twice weekly. That same guideline’s dosing table lists 17-beta-estradiol cream at 2 g daily for two weeks, then 1 g two to three times per week, and conjugated equine estrogen cream at 0.5 g daily for two weeks, then 0.5 g twice weekly. Family-medicine and menopause-society references describe the same for estradiol cream: about 0.5 to 1 g daily for two weeks, then a maintenance dose one to three times a week. Read these as the general pattern rather than a personal prescription. The exact amount and frequency should come from the instructions on your prescription, since the doses and the measuring marks are not the same across brands.
Where the cream goes
Aim for the lower third of the vagina rather than pushing the applicator high toward the cervix. Lower one-third application is probably preferred because it has less vascular connection with the uterus than the upper two-thirds. My practical advice to patients is “it needs to go far enough inside that it will stay there.”
Because the cream is spread by hand or applicator rather than delivered as a single fixed unit, a small amount can also be applied to the vulva and the vaginal opening for external dryness, burning, or irritation. Low-dose vaginal estrogen is the preferred hormonal treatment for the vulvar symptoms of GSM, not only the internal ones.
How soon it works
Give it time. Symptoms usually begin to improve over the first few weeks, but the full benefit can take about 8 to 12 weeks. If little has changed after the first week or two, keep going.
Cream compared with tablets and rings
The cream is soothing, but it can be messy, and messiness and inconvenience are among the most common reasons people stop using it. If that is a drawback for you, a tablet, insert, or ring delivers a similar low dose with less mess, and the approved formulations all work about equally well. Which one you use is mostly a matter of preference.
What the evidence does not settle
The sources do not identify a best time of day, so morning versus night is a matter of convenience. Some studied regimens happened to use a nightly application, but that does not make night more effective, so pick a time you will remember.
Technique has now been compared head to head. In a 2026 randomized trial of postmenopausal women with recurrent urinary tract infections, applying a small amount of cream around the urethra with a finger (about 0.5 g twice a week) prevented infections about as well as inserting a full applicator into the vagina (1 g twice a week). Roughly half of each group stayed infection-free at six months, and the finger group reported less vaginal itching. This was a single-center study aimed at preventing infections rather than relieving dryness, so it does not answer every question about technique, but it is good evidence that a smaller amount applied by finger can work as well as the applicator.
How I approach it
In practice, the most effective vaginal estrogen is the one that you can use reliably. If the mess of the cream becomes the reason someone skips doses, that is a good moment to switch to an insert or a ring, which reach the same tissue with less fuss.
References
- Anger J, Lee U, Ackerman AL, et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2019, Confirmed 2022, Amended 2025). American Urological Association / Canadian Urological Association / SUFU. 2019.
- Faubion SS, Sood R, Kapoor E. Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. Mayo Clinic Proceedings. 2017. doi:10.1016/j.mayocp.2017.08.019
- Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018. doi:10.1097/GME.0000000000001121
- Faubion SS, Kingsberg SA, Clark AL, et al. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020. doi:10.1097/GME.0000000000001609
- Ringel NE, Iglesia C. Common Benign Chronic Vulvar Disorders. American Family Physician. 2020.
- Zuo SW, Mowers EE, Hem S, et al. Vaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection: A Randomized Trial. Obstetrics & Gynecology. 2026. doi:10.1097/AOG.0000000000006376
← Learn more about Vaginal Estrogen